SINTX Technologies Reports Significant Revenue Drop and Evaluates New Strategic Focus in Q1 2025

SINTX Technologies, Inc. (NASDAQ: SINT) has recently reported its financial performance for the first quarter of 2025. The company focuses on advanced ceramics for biomedical and antipathogenic applications, having evolved from purely manufacturing medical devices to leveraging silicon nitride technology across various sectors.

Q1 2025 Financial Highlights:

• Total Revenue: $369,000, down 46% from $687,000 in Q1 2024.
• Product Revenue: $291,000, a slight decrease of 6% YoY.
• Grant and Contract Revenue: $78,000, a sharp decline of 79% due to the sale of its subsidiary, TA&T.
• Cost of Revenue: $246,000, up 10% YoY.
• Gross Profit: $123,000, representing a significant drop of 73% from $464,000 in the previous year.
• Total Operating Expenses: $2.5 million, reduced by 32% YoY from $3.7 million.
• Loss from Operations: $2.38 million, improved compared to a loss of $3.20 million in Q1 2024.
• Net Loss: $2.29 million, up from a loss of $886,000 in the same quarter last year.

Operational Developments:

• SINTX halted operations at its armor plant, incurring an impairment charge of approximately $4.6 million.
• A new strategic focus is being considered to prioritize advancements in the medical device sector, aiming to enhance patient outcomes.
• Regulatory compliance initiatives at the Salt Lake City facility continue, maintaining FDA and ISO certifications.
• Completed the sale of its subsidiary, TA&T, further simplifying operations.

Balance Sheet Snapshots:

• Cash and Cash Equivalents: $6.5 million, an increase from $3.6 million at the end of 2024.
• Total Assets: $11.45 million, up from $9.41 million at the end of 2024.
• Total Liabilities: $5.36 million, a decrease from $5.52 million.
• Total Stockholders’ Equity: $6.09 million, showing growth from $3.89 million.

Cash Flow Summary:

• Net Cash Used in Operating Activities: $1.3 million, less than the $2.7 million used in Q1 2024.
• Net Cash Used in Investing Activities: $63,000, down from $173,000 last year.
• Net Cash Provided by Financing Activities: $4.26 million, slightly lower than $5.33 million in 2024.
• Net Increase in Cash: $2.90 million, an improvement compared to $2.42 million in Q1 2024.

Outlook:

SINTX continues facing challenges with ongoing losses and the need for additional financing. The company expects to enhance its R&D efforts and sales strategies actively while managing operational costs efficiently. The transition towards a more focused approach in the medical device sector is anticipated to better position SINTX for future growth, despite expected volatility in revenues and profits.